Precision Neuro STALICLA focuses on neurodevelopmental and neuropsychiatric disorders with patient subgroup–matched precision medicine, presenting a targeted opportunity to partner on subpopulation-specific trials, biomarkers, and companion diagnostics.

Phase pipeline Current activities include Phase 2 trials for ASD subgroup treatment STP1 and Phase 3 efforts for cocaine use disorder STP7 in collaboration with NIDA, signaling potential for co-development, funding partnerships, and milestone-driven collaborations.

Strategic funding With a recent CHF financing round and investor activity (including Addex Therapeutics), there is readiness for alliance discussions, licensing, or joint development agreements to accelerate clinical programs.

Executive slate New leadership appointments on the board and scientific advisory team indicate a growing governance and strategic execution focus, creating entry points for partnership pitches, advisory roles, and senior collaboration dialogues.

Sustainability & stance As a Swiss clinical-stage biotech with a lean employee base and a multi-omics platform (DEPI), there are opportunities to offer services, software, or analytics collaborations around data platforms, real-world evidence generation, and regulatory-ready program support.